Possible association of anti-tumor necrosis factor-α antibody therapy with the development of scleroderma-like changes with lichen planus

Eur J Dermatol. 2015 Sep-Oct;25(5):513-5. doi: 10.1684/ejd.2015.2631.

Authors

Tomoko Inoue-Nishimoto¹, Takaaki Hanafusa², Ken Igawa³, Hiroaki Azukizawa¹, Akinori Yokomi¹, Hiroo Yokozeki³, Ichiro Katayama¹

Affiliations

¹ Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan.
² Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan., Department of Dermatology, Tokyo Medical and Dental University, Graduate School of Medicine, Yushima 1-5-45, Bunkyo-ku, Tokyo 113-8519, Japan.
³ Department of Dermatology, Tokyo Medical and Dental University, Graduate School of Medicine, Yushima 1-5-45, Bunkyo-ku, Tokyo 113-8519, Japan.

PMID: 26242643
DOI: 10.1684/ejd.2015.2631

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adalimumab / adverse effects*
Adalimumab / therapeutic use
Adult
Biopsy, Needle
Drug Eruptions / etiology
Drug Eruptions / pathology
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Immunohistochemistry
Lichen Planus / chemically induced*
Lichen Planus / drug therapy
Lichen Planus / pathology
Psoriasis / diagnosis
Psoriasis / drug therapy*
Risk Assessment
Scleroderma, Localized / chemically induced*
Scleroderma, Localized / drug therapy
Scleroderma, Localized / pathology
Severity of Illness Index
Treatment Outcome
Tumor Necrosis Factor-alpha / administration & dosage
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Tumor Necrosis Factor-alpha
Adalimumab